Consensus on graft-versus-host disease

Vaneuza Araújo Moreira Funke; João Victor Piccolo Feliciano; Giancarlo Fatobene; Maria Cláudia Rodrigues Moreira; Antonio Vaz de Macedo; Rita de Cássia Barbosa da Silva Tavares; Marcia de Matos Silva; Marcos Paulo Colella; Morgani Rodrigues; Luis Fernando da Silva Bouzas; Afonso Celso Vigorito

doi:10.46765/2675-374X.2025v7n1e361

Authors

Vaneuza Funke Universidade Federal do Paraná – Hospital de Clínicas – Curitiba (PR), Brazil. https://orcid.org/0000-0002-2122-7277
João Victor Feliciano Faculdade de Medicina de São José do Rio Preto – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0002-2034-7015
Giancarlo Fatobene Universidade de São Paulo – Faculdade de Medicina – Hospital das Clínicas – São Paulo (SP), Brazil. https://orcid.org/0000-0003-4145-049X
Maria Cláudia Moreira Instituto Nacional de Câncer – Centro de Transplante de Medula Óssea – Rio de Janeiro (RJ), Brazil|Universidade Federal do Rio de Janeiro – Faculdade de Medicina – Rio de Janeiro (RJ), Brazil. https://orcid.org/0000-0002-8376-7199
Antonio Vaz de Macedo Cancer Center Oncoclínicas – Belo Horizonte (MG), Brazil|Instituto Mário Penna – Hospital Luxemburgo – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0002-7633-8839
Rita de Cássia Barbosa da Silva Tavares Instituto Nacional de Câncer – Centro de Transplante de Medula Óssea – Rio de Janeiro (RJ), Brazil. https://orcid.org/0000-0002-9050-7918
Marcia de Matos Silva Instituto Nacional de Câncer – Centro de Transplante de Medula Óssea – Rio de Janeiro (RJ), Brazil|Universidade Federal do Rio de Janeiro – Faculdade de Medicina – Rio de Janeiro (RJ), Brazil. https://orcid.org/0000-0003-2038-5158
Marcos Paulo Colella Universidade Estadual de Campinas – Hospital das Clínicas – Campinas (SP), Brazil. https://orcid.org/0000-0002-4292-6472
Morgani Rodrigues Hospital Israelita Albert Einstein – São Paulo (SP), Brazil. https://orcid.org/0000-0002-0061-7882
Luis Fernando da Silva Bouzas Medicina Celular – Rio de Janeiro (RJ), Brazil. https://orcid.org/0000-0002-6267-9448
Afonso Celso Vigorito Universidade Estadual de Campinas – Hospital das Clínicas – Campinas (SP), Brazil. https://orcid.org/0000-0002-9990-1313

DOI:

https://doi.org/10.46765/2675-374X.2025v7n1e361

Keywords:

Graft vs Host Disease, Therapeutics, Consensus

Abstract

Graft-versus-host disease (GvHD) remains the mainly cause of late non-relapse mortality following allogeneic hematopoietic cell transplantation. Advancements in novel immunosuppressive therapies and prophylactic regimens necessitate an update to current clinical guidance. This consensus provides updated evidence-based recommendations for GVHD prophylaxis, alongside the treatment of acute and chronic disease.

References

1. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001 DOI: https://doi.org/10.1016/j.bbmt.2014.12.001

2. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606-15. https://doi.org/10.1182/blood-2014-08-551994 DOI: https://doi.org/10.1182/blood-2014-08-551994

3. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-9. https://doi.org/10.1182/blood-2010-08-302109 DOI: https://doi.org/10.1182/blood-2010-08-302109

4. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10. https://doi.org/10.1016/j.bbmt.2015.09.001 DOI: https://doi.org/10.1016/j.bbmt.2015.09.001

5. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401-15. https://doi.org/10.1038/s41409-018-0204-7 DOI: https://doi.org/10.1038/s41409-018-0204-7

6. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-14. https://doi.org/10.1182/blood.v100.2.406 DOI: https://doi.org/10.1182/blood.V100.2.406

7. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12(4):375-96. https://doi.org/10.1016/j.bbmt.2006.02.003 DOI: https://doi.org/10.1016/j.bbmt.2006.02.003

8. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714-20. https://doi.org/10.1182/blood-2010-12-323824 DOI: https://doi.org/10.1182/blood-2010-12-323824

9. Nash RA, Piñeiro LA, Storb R, Deeg HJ, Fitzsimmons WE, Furlong T, Hansen JA, Gooley T, Maher RM, Martin P, McSweeney PA, Sullivan KM, Anasetti C, Fay JW. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88(9):3634-41. DOI: https://doi.org/10.1182/blood.V88.9.3634.bloodjournal8893634

10. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999; 24(7): 763-8. https://doi.org/10.1038/sj.bmt.1701983 DOI: https://doi.org/10.1038/sj.bmt.1701983

11. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92(7):2303-14.

12. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062-8.

13. Inamoto Y, Flowers ME, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T, Kiem HP, Mielcarek MB, Nash RA, Storb RF, Witherspoon RP, Storer BE, Martin PJ. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant. 2011;17(7):1088-92. https://doi.org/10.1016/j.bbmt.2011.01.017 DOI: https://doi.org/10.1016/j.bbmt.2011.01.017

14. Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis. Leuk Res. 2014;38(3): 352-60. https://doi.org/10.1016/j.leukres.2013.12.012 DOI: https://doi.org/10.1016/j.leukres.2013.12.012

15. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(7):621-5. https://doi.org/10.1038/sj.bmt.1704647 DOI: https://doi.org/10.1038/sj.bmt.1704647

16. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937-47. https://doi.org/10.1016/j.bbmt.2010.01.010 DOI: https://doi.org/10.1016/j.bbmt.2010.01.010

17. Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014;2014(7):Cd010280. https://doi.org/10.1002/14651858.cd010280.pub2 DOI: https://doi.org/10.1002/14651858.CD010280.pub2

18. Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol. 2015;90(2):144-8. https://doi.org/10.1002/ajh.23882 DOI: https://doi.org/10.1002/ajh.23882

19. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):73-85. https://doi.org/10.1016/j.bbmt.2018.08.018 DOI: https://doi.org/10.1016/j.bbmt.2018.08.018

20. Hamilton BK, Rybicki LA, Li H, Lucas T, Corrigan D, Kalaycio M, Sobecks R, Hanna R, Rotz SJ, Dean RM, Gerds AT, Jagadeesh D, Brunstein C, Sauter CS, Copelan EA, Majhail NS. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Adv. 2023;7(16):4505-13. https://doi.org/10.1182/bloodadvances.2023010310 DOI: https://doi.org/10.1182/bloodadvances.2023010310

21. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. Int J Hematol. 2017;105(4):485-96. https://doi.org/10.1007/s12185-016-2154-4 DOI: https://doi.org/10.1007/s12185-016-2154-4

22. Ramzi M, Haghighat S, Namdari N, Haghighinejad H. Combination of low-dose, short-course mycophenolate mofetil with cyclosporine and methotrexate for graft-versus-host disease prophylaxis in allogeneic stem cell transplant. Exp Clin Transplant. 2021;19(12):1328-33. https://doi.org/10.6002/ect.2020.0004 DOI: https://doi.org/10.6002/ect.2020.0004

23. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372-7. https://doi.org/10.1182/blood-2014-04-567164 DOI: https://doi.org/10.1182/blood-2014-04-567164

24. Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/

sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(11):1417-25. https://doi.org/10.3324/haematol.2016.149294 DOI: https://doi.org/10.3324/haematol.2016.149294

25. Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate severe chronic graftversus-host disease. Haematologica. 2015;100(7):970-7. https://doi.org/10.3324/haematol.2015.123588 DOI: https://doi.org/10.3324/haematol.2015.123588

26. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012;97(12):1882-9. https://doi.org/10.3324/haematol.2012.067140 DOI: https://doi.org/10.3324/haematol.2012.067140

27. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224-30. https://doi.org/10.1182/blood-2009-11-251595 DOI: https://doi.org/10.1182/blood-2009-11-251595

28. Kanakry CG, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497-505. https://doi.org/10.1200/jco.2013.54.0625 DOI: https://doi.org/10.1200/JCO.2013.54.0625

29. Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502-8. https://doi.org/10.1182/blood-2015-10-672071 DOI: https://doi.org/10.1182/blood-2015-10-672071

30. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ. Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(1): 112-8. https://doi.org/10.1016/j.bbmt.2015.08.034 DOI: https://doi.org/10.1016/j.bbmt.2015.08.034

31. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Single-agent GVHD prophylaxis with post transplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124(25):3817-27. https://doi.org/10.1182/blood-2014-07-587477 DOI: https://doi.org/10.1182/blood-2014-07-587477

32. Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, Bondarenko S, Bourhis JH, Cornelissen JJ, Socié G, Koc Y, Canaani J, Savani B, Bug G, Spyridonidis A, Giebel S, Brissot E, Bazarbachi A, Esteve J, Mohty M. Graft-versus-host disease prophylaxis with post transplantation cyclophosphamide versus cyclosporine a and methotrexate in matched sibling donor transplantation. Transplant Cell Ther. 2022;28(2):86.e1-e8. https://doi.org/10.1016/j.jtct.2021.11.013 DOI: https://doi.org/10.1016/j.jtct.2021.11.013

33. Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C. High-dose cyclophosphamide and tacrolimus as graft-versus-host disease prophylaxis for matched and mismatched unrelated donor transplantation. Transplant Cell Ther. 2021;27(7):619.e1-e8. https://doi.org/10.1016/j.jtct.2021.03.022 DOI: https://doi.org/10.1016/j.jtct.2021.03.022

34. Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen JJ, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, Mohty M; Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. Leukemia. 2021;35(2):585-94. https://doi.org/10.1038/s41375-020-0863-4 DOI: https://doi.org/10.1038/s41375-020-0863-4

35. Galli E, Metafuni E, Giammarco S, Limongiello MA, Innocenti I, Autore F, Laurenti L, Sorà F, Chiusolo P, Teofili L, Bacigalupo A, Sica S. Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. Bone Marrow Transplant. 2022; 57(4): 532-7. https://doi.org/10.1038/s41409-022-01574-0 DOI: https://doi.org/10.1038/s41409-022-01574-0

36. Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, Koc Y, Gülbas Z, Vitek A, Sica S, Diez-Martin JL, Castagna L, Bruno B, Rovira M, Moiseev I, Martino M, Grillo G, Araujo MC, Bulabois CE, Nguyen S, Socié G, Arat M, Pavlu J, Tischer J, Martin H, Corral LL, Choi G, Forcade E, McDonald A, Pane F, Bazarbachi A, Ciceri F, Nagler A, Mohty M. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2022; 57(4): 562-71. https://doi.org/10.1038/s41409-022-01577-x DOI: https://doi.org/10.1038/s41409-022-01577-x

37. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O’Donnell L, O’Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022;40(4):356-68. https://doi.org/10.1200/jco.21.02293 DOI: https://doi.org/10.1200/JCO.21.02293

38. Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D’Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M. Post-transplant cyclophosphamide and tacrolimus–mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. Biol Blood Marrow Transplant. 2017; 23(3): 459-66. https://doi.org/10.1016/j.bbmt.2016.12.636 DOI: https://doi.org/10.1016/j.bbmt.2016.12.636

39. Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt-Baildon M, Scheid C. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96(1):27-35. https://doi.org/10.1111/ejh.12541 DOI: https://doi.org/10.1111/ejh.12541

40. Bailén R, Kwon M, Pascual-Cascón MJ, Ferrà C, Sanz J, Gallardo-Morillo A, García-Sola A, Torrent A, Jiménez-Lorenzo MJ, Piñana JL, Montoro J, Oarbeascoa G, Dorado N, Gómez-Centurión I, Muñoz C, Martínez-Laperche C, Anguita J, Buño I, Díez-Martín JL; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH). Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATGbased prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100(2):541-53. https://doi.org/10.1007/s00277-020-04317-7 DOI: https://doi.org/10.1007/s00277-020-04317-7

41. Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, Nakamae M, Nishimoto M, Kuno M, Makuuchi Y, Harada N, Takakuwa T, Hino M. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115(1):77-86. https://doi.org/10.1007/s12185-021-03228-1 DOI: https://doi.org/10.1007/s12185-021-03228-1

42. Al Malki MM, Tsai NC, Palmer J, Mokhtari S, Tsai W, Cao T, Ali H, Salhotra A, Arslan S, Aldoss I, Karras N, Karanes C, Zain J, Khaled S, Stein A, Snyder D, Marcucci G, Forman SJ, Nakamura R. Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Adv. 2021;5(12):2650-9. https://doi.org/10.1182/bloodadvances.2021004192 DOI: https://doi.org/10.1182/bloodadvances.2021004192

43. Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR; Australasian Leukaemia and Lymphoma Group. Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin. N Engl J Med. 2025;393(3):243-54. https://doi.org/10.1056/nejmoa2503189 DOI: https://doi.org/10.1056/NEJMoa2503189

44. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post transplant cyclophosphamide. J Clin Oncol. 2021;39(18):1971-82. https://doi.org/10.1200/jco.20.03502 DOI: https://doi.org/10.1200/JCO.20.03502

45. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol. 2021; 39(17): 1865-77. https://doi.org/10.1200/jco.20.01086 DOI: https://doi.org/10.1200/JCO.20.01086

46. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-400. https://doi.org/10.1182/blood.V97.11.3390 DOI: https://doi.org/10.1182/blood.V97.11.3390

47. Ueda Oshima M, Storer BE, Qiu H, Chauncey T, Asch J, Boyer MW, Giaccone L, Flowers M, Mielcarek M, Storb R, Maloney DG, Sandmaier BM. Long-term outcomes with nonmyeloablative HLA-identical related hematopoietic cell transplantation using tacrolimus and mycophenolate mofetil for graft-versus-host disease prophylaxis. Transplant Cell Ther. 2021;27(2):163.e1-e7. https://doi.org/10.1016/j.jtct.2020.10.016 DOI: https://doi.org/10.1016/j.jtct.2020.10.016

48. Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, Martínez C, Brunet S, Sureda A, Carreras E, Sierra J. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reducedintensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant. 2010; 45(9): 1449-56. https://doi.org/10.1038/bmt.2009.362 DOI: https://doi.org/10.1038/bmt.2009.362

49. Michallet M, Sobh M, Barraco F, Thomas X, Balsat M, Lejeune C, Ducastelle S, Renault M, Tedone N, Labussiere H, Nicolini FE. Addition of more immunosuppressive drugs as graft-versus-host disease (GVHD) prophylaxis does not improve GVHD outcomes in reduced intensity allogeneic hematopoietic cell transplantation from unrelated donors. Blood. 2016;128(22):5786. https://doi.org/10.1182/blood.V128.22.5786.5786 DOI: https://doi.org/10.1182/blood.V128.22.5786.5786

50. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graftversus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132-e43. https://doi.org/10.1016/s2352-3026(18)30221-7 DOI: https://doi.org/10.1016/S2352-3026(18)30221-7

51. De Jong CN, Meijer E, Bakunina K, Nur E, van Marwijk Kooij M, de Groot MR, van Gelder M, Maertens JA, Kuball JHE, Deeren D, van der Holt B, Cornelissen JJ, Broers AEC. Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors. Blood. 2019; 134 (Suppl. 1): 1. https://doi.org/10.1182/blood-2019-124659 DOI: https://doi.org/10.1182/blood-2019-124659

52. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338-48. https://doi.org/10.1056/NEJMoa2215943 DOI: https://doi.org/10.1056/NEJMoa2215943

53. Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, Yakoub-Agha I, Srour M, Bulabois CE, Huynh A, Chantepie S, Menard AL, Rubio MT, Ceballos P, Dulery R, Furst S, Malard F, Blaise D, Mohty M. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024; 14 (1): 31. https://doi.org/10.1038/s41408-024-00990-3 DOI: https://doi.org/10.1038/s41408-024-00990-3

54. Paviglianiti A, Ngoya M, Peña M, Boumendil A, Gülbas Z, Ciceri F, Bonifazi F, Russo D, Fegueux N, Stolzel F, Bulabois CE, Socié G, Forcade E, Solano C, Finel H, Robinson S, Glass B, Montoto S. Graft-versus-host disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024;59(5):597-603. https://doi.org/10.1038/s41409-024-02225-2 DOI: https://doi.org/10.1038/s41409-024-02225-2

55. Rappazzo KC, Zahurak M, Bettinotti M, Ali SA, Ambinder AJ, Bolaños-Meade J, Borrello I, Dezern AE, Gladstone D, Gocke C, Fuchs E, Huff CA, Imus PH, Jain T, Luznik L, Rahmat L, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post-transplantation cyclophosphamide. Transplant Cell Ther. 2021; 27 (11): 909.e1-e6. https://doi.org/10.1016/j.jtct.2021.08.013 DOI: https://doi.org/10.1016/j.jtct.2021.08.013

56. Kornblit B, Storer BE, Andersen NS, Maris MB, Chauncey TR, Petersdorf EW, Woolfrey AE, Flowers MED, Storb R, Maloney DG, Sandmaier BM. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. Blood. 2020;136(13):1499-506. https://doi.org/10.1182/blood.2020005338 DOI: https://doi.org/10.1182/blood.2020005338

57. Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil based graftversus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019; 6(8): e409-18. https://doi.org/10.1016/s2352-3026(19)30088-2 DOI: https://doi.org/10.1016/S2352-3026(19)30088-2

58. Wegener A, Andersen NS, Friis LS, Petersen SL, Schjødt I, Kornblit B, Sengeløv H, Gjærde LK. Triple-drug graft-versus-host disease prophylaxis after HLA-matched unrelated donor nonmyeloablative allogenic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023;29(9):575.e1-e6. https://doi.org/10.1016/j.jtct.2023.05.022 DOI: https://doi.org/10.1016/j.jtct.2023.05.022

59. Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43-53. https://doi.org/10.1056/nejmoa1506002 DOI: https://doi.org/10.1056/NEJMoa1506002

60. Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma. 2017; 58 (8):1840-8. https://doi.org/10.1080/10428194.2016.1266624 DOI: https://doi.org/10.1080/10428194.2016.1266624

61. Theurich S, Fischmann H, Shimabukuro‐Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt‐Baildon M. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2012 (9): Cd009159. https://doi.org/10.1002/14651858.CD009159.pub2 DOI: https://doi.org/10.1002/14651858.CD009159.pub2

62. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-7. https://doi.org/10.1182/blood.v98.10.2942 DOI: https://doi.org/10.1182/blood.V98.10.2942

63. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10(9): 855-64. https://doi.org/10.1016/s1470-2045(09)70225-6 DOI: https://doi.org/10.1016/S1470-2045(09)70225-6

64. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-82. DOI: https://doi.org/10.1182/blood-2011-01-329821

65. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Canadian Blood and Marrow Transplant Group. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016; 17(2): 164-73. https://doi.org/10.1016/s1470-2045(15)00462-3 DOI: https://doi.org/10.1016/S1470-2045(15)00462-3

66. Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(2):224-34. https://doi.org/10.3324/haematol.2016.148510 DOI: https://doi.org/10.3324/haematol.2016.148510

67. Chakupurakal G, Freudenberger P, Skoetz N, Ahr H, Theurich S. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2023;6(6):Cd009159. https://doi.org/10.1002/14651858.cd009159.pub3 DOI: https://doi.org/10.1002/14651858.CD009159.pub3

68. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019;54(7):1094-106. https://doi.org/10.1038/s41409-018-0393-0 DOI: https://doi.org/10.1038/s41409-018-0393-0

69. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Cell Therapy Transplant Canada. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7(2):e100-11. https://doi.org/10.1016/s2352-3026(19)30220-0 DOI: https://doi.org/10.1016/S2352-3026(19)30220-0

70. Chang YJ, Wu DP, Lai YR, Liu QF, Sun YQ, Hu J, Hu Y, Zhou JF, Li J, Wang SQ, Li W, Du X, Lin DJ, Ren HY, Chen FP, Li YH, Zhang X, Huang H, Song YP, Jiang M, Hu JD, Liang YM, Wang JB, Xiao Y, Huang XJ. Antithymocyte Globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, openlabel, randomized controlled study. J Clin Oncol. 2020;38(29):3367-76. https://doi.org/10.1200/jco.20.00150 DOI: https://doi.org/10.1200/JCO.20.00150

71. Yang X, Li D, Xie Y. Anti-thymocyte globulin prophylaxis in patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation: an updated meta-analysis. Front Oncol. 2021;11:717678. https://doi.org/10.3389/fonc.2021.717678 DOI: https://doi.org/10.3389/fonc.2021.717678

72. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003-11. https://doi.org/10.1200/jco.2017.75.8177 DOI: https://doi.org/10.1200/JCO.2017.75.8177

73. Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-Tlymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4(6):e293-e301. https://doi.org/10.1016/s2352-3026(17)30081-9 DOI: https://doi.org/10.1016/S2352-3026(17)30081-9

74. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86. https://doi.org/10.1053/bbmt.2002.v8.pm12171484 DOI: https://doi.org/10.1053/bbmt.2002.v8.pm12171484

75. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-50. https://doi.org/10.1016/j.bbmt.2008.03.005 DOI: https://doi.org/10.1016/j.bbmt.2008.03.005

76. Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152-61. https://doi.org/10.1200/jco.2014.60.4777 DOI: https://doi.org/10.1200/JCO.2014.60.4777

77. Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021;5(5):1154-63. https://doi.org/10.1182/bloodadvances.2020003779 DOI: https://doi.org/10.1182/bloodadvances.2020003779

78. Esquirol A, Pascual MJ, Montoro J, Piñana JL, Ferrà C, Herruzo B, Garcia-Cadenas I, Balaguer A, Perez A, Huguet M, Redondo S, Villalba M, Hernandez-Boluda JC, Chorao P, Hernani R, Sanz J, Solano C, Sierra J, Martino R. Comparison of three graft-versus-host disease prophylaxis strategies after T cell-replete haploidentical hematopoietic transplantation: tacrolimus versus calcineurin inhibitors + mycophenolate mofetil versus sirolimus + mycophenolate mofetil. Transplant Cell Ther. 2024;30(10):1025.e1-e14. https://doi.org/10.1016/j.jtct.2024.07.027 DOI: https://doi.org/10.1016/j.jtct.2024.07.027

79. Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2024;30(2):229.e1-e11. https://doi.org/10.1016/j.jtct.2023.11.010 DOI: https://doi.org/10.1016/j.jtct.2023.11.010

80. Hernani R, Piñana JL, Pérez A, Quintero A, Montoro J, Hernández-Boluda JC, Carretero C, Balaguer-Roselló A, Guerreiro M, Lorenzo I, Aguilar C, Giménez E, Navarro D, Sanz MA, Sanz J, Solano C. Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. EJHaem. 2021;2(2):236-48. https://doi.org/10.1002/jha2.183 DOI: https://doi.org/10.1002/jha2.183

81. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-73. https://doi.org/10.1182/blood-2005-05-2146 DOI: https://doi.org/10.1182/blood-2005-05-2146

82. Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, Wang X, Guo S, Zhan X, Fu Y, Song Y, Zhou J. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Br J

Haematol. 2023;200(2):210-21. https://doi.org/10.1111/bjh.18483 DOI: https://doi.org/10.1111/bjh.18483

83. Duléry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, Maisano V, Chabannon C, Malard F, Brissot E, Sestili S, Banet A, Van de Wyngaert Z, Belhocine R, Ederhy S, Castagna L, Bramanti S, Blaise D, Mohty M, Fürst S, Devillier R. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2023;58(4):386-92. https://doi.org/10.1038/s41409-022-01908-y DOI: https://doi.org/10.1038/s41409-022-01908-y

84. Hyder MA, Dimitrova D, Sabina R, DeVries A, McCune JS, McAdams MJ, Flomerfelt FA, McKeown C, Sadler JL, Chai A, Hughes TE, Napier S, Stokes A, Sponaugle J, Rechache K, Parta M, Cuellar-Rodriguez J, Figg WD, Choo-Wosoba H, Steinberg SM, Kanakry JA, Kanakry CG. Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation. Blood Adv. 2025;9(10):2553-69. https://doi.org/10.1182/bloodadvances.2024014879 DOI: https://doi.org/10.1182/bloodadvances.2024014879

85. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F, Giorgiani G, Arcese W, Iori AP, Falda M, Bosi A, Miniero R, Alessandrino P, Dini G, Rotoli B, Bacigalupo A. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92(7):2288-93.

86. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, Nash RA, Flowers ME, Doney K, Lee S, Marr KA, Furlong T, Storb R, Appelbaum FR, Martin PJ. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009; 113 (13): 2888-94. https://doi.org/10.1182/blood-2008-07-168401 DOI: https://doi.org/10.1182/blood-2008-07-168401

87. McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, Murakami C, Levine DS. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998;115(1):28-35. https://doi.org/10.1016/s0016-5085(98)70361-0 DOI: https://doi.org/10.1016/S0016-5085(98)70361-0

88. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109(10):4557-63. https://doi.org/10.1182/blood-2006-05-021139 DOI: https://doi.org/10.1182/blood-2006-05-021139

89. Rostagno E, Campanati A, Mordini N, Cannici C, Cioce M, De Cecco V, Samarani E, Foà R, Olivieri A, Botti S. Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. J Eur Acad Dermatol Venereol. 2022;36(7):1003-15. https://doi.org/10.1111/jdv.18074 DOI: https://doi.org/10.1111/jdv.18074

90. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR, Martin PJ. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51. https://doi.org/10.1182/blood.v100.1.48 DOI: https://doi.org/10.1182/blood.V100.1.48

91. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56. https://doi.org/10.1016/j.bbmt.2005.09.004 DOI: https://doi.org/10.1016/j.bbmt.2005.09.004

92. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-63. https://doi.org/10.1016/j.bbmt.2012.04.005 DOI: https://doi.org/10.1016/j.bbmt.2012.04.005

93. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511-7. https://doi.org/10.1182/blood-2009-03-212290 DOI: https://doi.org/10.1182/blood-2009-03-212290

94. Furlong T, Martin P, Flowers ME, Carnevale-Schianca F, Yatscoff R, Chauncey T, Appelbaum FR, Deeg HJ, Doney K, Witherspoon R, Storer B, Sullivan KM, Storb R, Nash RA. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009;44(11):739-48. https://doi.org/10.1038/bmt.2009.76 DOI: https://doi.org/10.1038/bmt.2009.76

95. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005; 84 (10): 681-5. https://doi.org/10.1007/s00277-005-1070-0 DOI: https://doi.org/10.1007/s00277-005-1070-0

96. Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol. 2013;4(5):320-34. https://doi.org/10.1177/2040620713490316 DOI: https://doi.org/10.1177/2040620713490316

97. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, Mitterbauer M, Rabitsch W, Schulenburg A, Kalhs P. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405-8.

98. Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein UM, Kröger N. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GItract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant. 2020;55(12):2286-93. https://doi.org/10.1038/s41409-020-0952-z DOI: https://doi.org/10.1038/s41409-020-0952-z

99. Schneiderman J. Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2017;2017(1):639-44. https://doi.org/10.1182/asheducation-2017.1.639 DOI: https://doi.org/10.1182/asheducation-2017.1.639

100. Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677-86. https://doi.org/10.1016/j.bbmt.2014.05.017 DOI: https://doi.org/10.1016/j.bbmt.2014.05.017

101. Rafei H, Kharfan-Dabaja MA, Nishihori T. A critical appraisal of extracorporeal photopheresis as a treatment modality for acute and chronic graft-versus-host disease. Biomedicines. 2017;5(4):60. https://doi.org/10.3390/biomedicines5040060 DOI: https://doi.org/10.3390/biomedicines5040060

102. Shapiro RM, Antin JH. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020;13(5):519-32. https://doi.org/10.1080/17474086.2020.1752175 DOI: https://doi.org/10.1080/17474086.2020.1752175

103. Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, Sala ML, Donnini I, Chiusolo P, Mussetti A, Battista M, Turra A, Cattina F, Rambaldi B, Schieppati F, Polverelli N, Bernardi S, Perucca S, Marini M, Laszlo D, Savignano C, Patriarca F, Corradini P, Piccirillo N, Sica S, Bosi A, Russo D. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo Italiano Trapianto di Midollo Osseo. Transplantation. 2016;100(12):e147-55. https://doi.org/10.1097/tp.0000000000001466 DOI: https://doi.org/10.1097/TP.0000000000001466

104. Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G. Extracorporeal photopheresis versus anticytokine therapy as a secondline treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013;19(7):1129-33. https://doi.org/10.1016/j.bbmt.2013.04.018 DOI: https://doi.org/10.1016/j.bbmt.2013.04.018

105. Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F, Hönigsmann H, Knobler RM. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96(7):2426-31. DOI: https://doi.org/10.1182/blood.V96.7.2426

106. Oarbeascoa G, Lozano ML, Guerra LM, Amunarriz C, Andon Saavedra C, Garcia-Gala JM, Viejo A, Revilla N, Acosta Fleitas C, Arroyo JL, Martinez Revuelta E, Galego A, Hernandez-Maraver D, Kwon M, Diez-Martin JL, Pascual C. Retrospective multicenter study of extracorporeal photopheresis in steroid-refractory acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(4):651-8. https://doi.org/10.1016/j.bbmt.2019.12.769 DOI: https://doi.org/10.1016/j.bbmt.2019.12.769

107. Sestili S, Eder S, Belhocine R, Dulery R, Battipaglia G, Brissot E, Mediavilla C, Banet A, van de Wyngaert Z, Paviglianiti A, Ledraa T, Bonin A, Mohty M, Malard F. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A singlecenter experience. Cytotherapy. 2020;22(8):445-9. https://doi.org/10.1016/j.jcyt.2020.03.003 DOI: https://doi.org/10.1016/j.jcyt.2020.03.003

108. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK, Wagner JE, Blazar BR. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8(1):40-6. https://doi.org/10.1053/bbmt.2002.v8.pm11858189 DOI: https://doi.org/10.1053/bbmt.2002.v8.pm11858189

109. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr Transplant. 2003;7(Suppl. 3):19-31. https://doi.org/10.1034/j.1399-3046.7.s3.3.x DOI: https://doi.org/10.1034/j.1399-3046.7.s3.3.x

110. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dörken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(12):899-903. https://doi.org/10.1038/sj.bmt.1703737 DOI: https://doi.org/10.1038/sj.bmt.1703737

111. Funke VA, Medeiros CR, Setúbal DC, Ruiz J, Bitencourt MA, Bonfim CM, Neto JZ, Pasquini R. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant. 2006;37(10):961-5. https://doi.org/10.1038/sj.bmt.1705306 DOI: https://doi.org/10.1038/sj.bmt.1705306

112. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104(3):649-54. https://doi.org/10.1182/blood-2003-12-4241 DOI: https://doi.org/10.1182/blood-2003-12-4241

113. Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, DiPersio JF. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9(10):e109799. https://doi.org/10.1371/journal.pone.0109799 DOI: https://doi.org/10.1371/journal.pone.0109799

114. Schroeder MA, Choi J, Staser K, DiPersio JF. The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia. Biol Blood Marrow Transplant. 2018;24(6):1125-34. https://doi.org/10.1016/j.bbmt.2017.12.797 DOI: https://doi.org/10.1016/j.bbmt.2017.12.797

115. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739-49. https://doi.org/10.1182/blood.2020004823 DOI: https://doi.org/10.1182/blood.2020004823

116. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-10. https://doi.org/10.1056/nejmoa1917635 DOI: https://doi.org/10.1056/NEJMoa1917635

117. Uygun V, Karasu G, Daloğlu H, Öztürkmen S, Kılıç SÇ, Yalçın K, Çelen SS, Hazar V, Yeşilipek A. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. Pediatr Blood Cancer. 2020;67(4):e28190. https://doi.org/10.1002/pbc.28190 DOI: https://doi.org/10.1002/pbc.28190

118. Dotoli GM, Santis GC, Orellana MD, Lima Prata K, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo AT, Hamerschlak N, Simões BP, Covas DT. Mesenchymal stromal cell infusion to treat steroid refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(6):859-62. https://doi.org/10.1038/bmt.2017.35 DOI: https://doi.org/10.1038/bmt.2017.35

119. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, Shaw BE; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012;158(1):62-78. https://doi.org/10.1111/j.1365-2141.2012.09131.x DOI: https://doi.org/10.1111/j.1365-2141.2012.09131.x

120. Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME; UVADEX Chronic GVHD Study Group. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17(12): 1775-82. https://doi.org/10.1016/j.bbmt.2011.05.004 DOI: https://doi.org/10.1016/j.bbmt.2011.05.004

121. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-74. https://doi.org/10.1182/blood-2008-03-141481 DOI: https://doi.org/10.1182/blood-2008-03-141481

122. Greinix HT, Worel N, Just U, Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014;50(3):349-57. https://doi.org/10.1016/j.transci.2014.04.005 DOI: https://doi.org/10.1016/j.transci.2014.04.005

123. Perotti C, Sniecinski I. A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! Transfus Apher Sci. 2015;52(3):360-8. https://doi.org/10.1016/j.transci.2015.04.011 DOI: https://doi.org/10.1016/j.transci.2015.04.011

124. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074-82. https://doi.org/10.1182/blood-2009-02-202937 DOI: https://doi.org/10.1182/blood-2009-02-202937

125. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O’Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, Forman S. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(4):307-13. https://doi.org/10.1016/j.bbmt.2005.01.011 DOI: https://doi.org/10.1016/j.bbmt.2005.01.011

126. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of CD4+CD25+regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108(1):390-9. https://doi.org/10.1182/blood-2006-01-0329 DOI: https://doi.org/10.1182/blood-2006-01-0329

127. Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A, Caballero D, Sierra J, Ribera JM, Díez JL. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(6):701-6. https://doi.org/10.1016/j.bbmt.2007.02.003 DOI: https://doi.org/10.1016/j.bbmt.2007.02.003

128. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, Lima MJ, Andersson B, Neumann J, Champlin R. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005; 130 (3): 409-17. https://doi.org/10.1111/j.1365-2141.2005.05616.x DOI: https://doi.org/10.1111/j.1365-2141.2005.05616.x

129. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-62. https://doi.org/10.1182/blood-2006-01-0233 DOI: https://doi.org/10.1182/blood-2006-01-0233

130. von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation. 2008;86(6):875-9. https://doi.org/10.1097/tp.0b013e318183f662 DOI: https://doi.org/10.1097/TP.0b013e318183f662

131. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2016;22(2):319-27. https://doi.org/10.1158/1078-0432.ccr-15-1443 DOI: https://doi.org/10.1158/1078-0432.CCR-15-1443

132. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709-18. https://doi.org/10.1182/blood-2009-02-204156 DOI: https://doi.org/10.1182/blood-2009-02-204156

133. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H, Funke VA, Storb R, Flowers ME. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 2005;36(4):337-41. https://doi.org/10.1038/sj.bmt.1705022 DOI: https://doi.org/10.1038/sj.bmt.1705022

134. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant. 2008; 41 (6): 571-7. https://doi.org/10.1038/sj.bmt.1705922 DOI: https://doi.org/10.1038/sj.bmt.1705922

135. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-50. https://doi.org/10.1182/blood-2017-07-793786 DOI: https://doi.org/10.1182/blood-2017-07-793786

136. Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved secondline therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2(15):2012-9. https://doi.org/10.1182/bloodadvances.2018013060 DOI: https://doi.org/10.1182/bloodadvances.2018013060

137. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021; 385 (3): 228-38. https://doi.org/10.1056/nejmoa2033122 DOI: https://doi.org/10.1056/NEJMoa2033122

138. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138 (22):2278-89. https://doi.org/10.1182/blood.2021012021 DOI: https://doi.org/10.1182/blood.2021012021

139. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O’Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Axatilimab in recurrent or refractory chronic graft-versus-host disease. N Engl J Med. 2024;391(11):1002-14. https://doi.org/10.1056/nejmoa2401537 DOI: https://doi.org/10.1056/NEJMoa2401537

Consensus on graft-versus-host disease

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Make a Submission

Keywords

Index

Information

Consensus on graft-versus-host disease

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Make a Submission

Keywords

Index

Social Media

Information